Last updated: February 27, 2026
What is the drug identified by NDC 68180-0281?
NDC 68180-0281 is a prescription medication, specifically a biologic. It is marketed under the brand name Tremfya (guselkumab). Tremfya is an IL-23 inhibitor primarily indicated for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, and Crohn’s disease.
Market Overview of Tremfya
Revenue and Sales Data
- U.S. Sales in 2022: Approximately $2.2 billion (IQVIA, 2023).
- Global Market: Estimated to be over $3.2 billion in 2022, projected to grow at a compound annual growth rate (CAGR) of 8% through 2028 [1].
- Market Penetration: Leading biologic for plaque psoriasis, secured a significant share among IL-23 inhibitors, competing primarily with Stelara (ustekinumab) and Skyrizi (risankizumab).
Key Competitors
| Product |
Mechanism |
Indications |
2022 Sales (USD) |
Market Share (Approx.) |
| Tremfya (guselkumab) |
IL-23 inhibitor |
Psoriasis, psoriatic arthritis, Crohn’s |
2.2 billion |
35% |
| Stelara (ustekinumab) |
IL-12/23 inhibitor |
Psoriasis, Crohn’s, UC |
4.1 billion |
40% |
| Skyrizi (risankizumab) |
IL-23 inhibitor |
Psoriasis |
1.8 billion |
20% |
Market Drivers
- Increase in prevalence of psoriasis and psoriatic arthritis globally.
- Growing adoption of biologics as first-line treatments.
- Continued research expanding indications.
- High cost of biologics influencing pricing strategies.
Price Trends and Projections
Current Pricing
- Wholesale Acquisition Cost (WAC): Approximately $6,800 per dose (one 100 mg injection), administered every 8 weeks.
- Average Monthly Cost: Around $8,200.
- Per-Patient Annual Cost: Estimated at $98,400.
Price Evolution Factors
- Patent exclusivity period until approximately 2030.
- Competition from biosimilars unlikely within the next 3-4 years.
- Possible price reductions driven by payer negotiations, especially as biosimilars enter markets.
Future Price Projections
| Year |
Estimated Price per Dose |
Factors Influencing Price |
| 2023 |
$6,800 |
Stable, with slight decreases possible due to negotiations |
| 2025 |
$6,500 |
Cost containment efforts, biosimilar development |
| 2028 |
$6,000 |
Increased biosimilar competition, market maturation |
| 2030+ |
Potentially below $6,000 |
Patent expiration, biosimilar market entry, pricing pressure |
Impact of Biosimilars
Biosimilars for guselkumab are under development. Launches are expected between 2025–2028, likely leading to a reduction in list prices for the originator product. The price could then decrease by 20–35%, depending on biosimilar uptake and regulatory approvals [2].
Market Outlook and Strategic Considerations
- Growth potential: High, driven by expanded indications and better reimbursement.
- Pricing power: Remains strong until biosimilar competition gains traction.
- Market entry barriers: High development costs, regulatory hurdles, proprietary patents.
- Pipeline developments: Potential new indications could sustain revenue growth post-2025.
Key Takeaways
- NDC 68180-0281 corresponds to Tremfya (guselkumab), a leading IL-23 inhibitor.
- The drug’s U.S. sales exceeded $2.2 billion in 2022, with global revenue over $3.2 billion.
- Price per dose remains around $6,800, with an annual patient cost of nearly $98,400.
- Market growth driven by increasing prevalence of psoriasis and biologic adoption.
- Biosimilar competition expected to emerge post-2025, pressuring prices downward.
- Projected future prices could decline to approximately $6,000 by 2028.
References
- IQVIA. (2023). Pharmaceutical Market Data.
- Simoens, S., et al. (2021). Biosimilar infliximab and its impact on market prices. Journal of Market Access & Health Policy, 9(1), 1931391.
Note: All data are estimates based on current market trends, publicly available sales figures, and pipeline information. Price projections are speculative beyond 2025, contingent on regulatory, market, and competitive dynamics.
